Will partnering in Europe be worthwhile for your company?
To help answer this question, we analyzed 43 licensing deals for pharmaceutical products in which Europe was the major territory for a foreign partner between January 2012 and August 2019.
Inside you will find discussion and graphs addressing:
- Total deal size;
- Upfront and equity payments;
- Development, commercial and total milestones;
- Number of products in a deal;
- Therapeutic area and deal value;
- Phase of development and deal value;
- Type of technology;
- Nationality of licensee;
- Conclusions; and
Sign-up below to gain access to the full report (PDF):